This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.
GlaxoSmithKline receives approval in 15 European countries for use of Relenza in prevention of influenza A and B
Issued – Thursday 24 August 2006, London, UK
GlaxoSmithKline (GSK) today announces that it has received approval from European Regulators in 15 EU countries for use of its anti-viral Relenza ® (zanamivir for inhalation) in the prevention (prophylaxis) of influenza A and B in adults and children 5 years of age and above.
Approval was also received today for the treatment of influenza in children 5 years of age and above. Relenza ® is already approved in Europe for the treatment of influenza in adults and adolescents 12 years of age and above.
Relenza ® won US FDA approval for the prevention of influenza in adults and children aged 5 years and older in March 2006.
“This approval is a significant step forward as it provides the medical community in Europe with another option to prevent and treat seasonal influenza enabling governments to prepare for a potential flu pandemic,” said David Stout, President Pharmaceutical Operations, GSK. “As a leading provider of vaccines and anti-viral medications, GSK is committed to support governments and health authorities around the world in planning to respond to a global crisis should an influenza pandemic occur.”
About GlaxoSmithKline
GlaxoSmithKline has an active research and development programme targeted at both seasonal and pandemic influenza, and has committed over $2 billion to expand capacity for manufacturing flu vaccine and its anti-viral influenza treatment Relenza®.
GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and health care companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: www.gsk.com.
Enquiries:
|
UK Media enquiries:
|
Philip Thomson
Gwenan Evans
Alice Hunt
|
(020) 8047 5502
(020) 8047 5502
(020) 8047 5502
|
|
US Media enquiries
|
Nancy Pekarek
Mary Anne Rhyne
Patricia Seif
|
(215) 751 7709
(919) 483 2839
(215) 751 7709
|
|
European Analyst/
Investor enquiries:
|
Anita Kidgell
Jen Hill
David Mawdsley
|
(020) 8047 5542
(020) 8047 5543
(020) 8047 5564
|
|
US Analyst/ Investor
enquiries:
|
Frank Murdolo
Tom Curry
|
(215) 751 7002
|
